Kymanox has launched AI-enabled quality and regulatory services for pharmaceutical, biotechnology, medical-device and combination-product companies, aimed at three documentation-heavy workflows. The Kymanox AI quality and regulatory offering matters because its proposed role is not to hand over automated output untouched: Kymanox says qualified subject-matter experts review and verify every AI-assisted deliverable before it reaches a client.
The consulting firm calls its underlying system the Kymanox Artificial Intelligence Engine, or KAI Engine, and describes it as built for regulated work. The announcement does not provide customer deployments, validation results, performance metrics, pricing, or regulatory clearances for the tools.
Kymanox’s initial services cover quality-management-system work, batch-release report review, and human-factors study optimization. In the first category, the company says the system assists with drafting documents, gap analyses and harmonizing quality-management documentation.
For batch release, Kymanox says its system examines paper batch records and related release documents for documentation discrepancies, data-integrity concerns and possible deviations to support batch disposition. The company describes the tool as an aid to review, rather than an autonomous release decision-maker.
What does Kymanox AI quality and regulatory work do?
The third workflow is a partnership with Sanai. The human-factors offering runs on Sanai’s proprietary platform, customized and deployed for Kymanox, and is intended to aggregate, review and summarize human-factors study data. Kymanox says that work supports usability analysis and regulatory-ready reporting for combination products and medical devices.
David Dlugo, Kymanox’s senior director of quality, said the company was rolling out the initial functions deliberately. Its stated operating model places AI in the assistive layer while its qualified experts conduct the review and verification step before delivery.
That distinction has practical weight in regulated documentation, where Kymanox is pitching AI-assisted batch-release review services alongside conventional consulting work. FDA’s 2018 guidance on drug current good manufacturing practice addresses the creation and handling of data, and says strategies for systems and controls should consider risks to patients, processes and products. The guidance is nonbinding and does not assess or endorse Kymanox’s services.
Kymanox says its governance framework includes human-in-the-loop oversight, disclosure of AI use on each engagement, documented workflows aligned with GxP expectations, and ongoing monitoring of performance and accuracy. It also says its environment uses encryption, role-based access controls and separate client data, and that client data is not used to train AI models.
The capabilities are available to clients that approve their use as part of an engagement, according to Kymanox. Chief executive Evan Edwards said the company sees governed AI as a differentiator; Kymanox plans additional AI-enabled, expert-verified service areas in late 2026 and 2027.
